Chemed Corp. (CHE) VP Sells $166,567.50 in Stock
Chemed Corp. (NYSE:CHE) VP Naomi C. Dallob sold 750 shares of the stock in a transaction dated Tuesday, October 31st. The stock was sold at an average price of $222.09, for a total transaction of $166,567.50. Following the completion of the sale, the vice president now directly owns 9,097 shares in the company, valued at $2,020,352.73. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Shares of Chemed Corp. (CHE) traded down 0.06% during midday trading on Wednesday, hitting $223.30. 79,084 shares of the stock were exchanged. The firm’s 50 day moving average price is $202.61 and its 200-day moving average price is $200.42. The stock has a market cap of $3.57 billion, a P/E ratio of 55.40 and a beta of 1.13. Chemed Corp. has a 52-week low of $132.92 and a 52-week high of $233.50.
Chemed Corp. (NYSE:CHE) last announced its quarterly earnings data on Thursday, October 26th. The company reported $2.15 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.00 by $0.15. The company had revenue of $417.40 million during the quarter, compared to the consensus estimate of $414.34 million. Chemed Corp. had a return on equity of 27.69% and a net margin of 4.62%. The firm’s revenue was up 6.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.73 EPS. On average, equities research analysts expect that Chemed Corp. will post $8.33 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Chemed Corp. (CHE) VP Sells $166,567.50 in Stock” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/11/01/chemed-corp-che-vp-sells-166567-50-in-stock.html.
A number of brokerages have recently issued reports on CHE. KeyCorp reissued a “hold” rating on shares of Chemed Corp. in a report on Friday, October 27th. TheStreet raised shares of Chemed Corp. from a “c+” rating to an “a-” rating in a report on Friday, October 27th. Royal Bank Of Canada increased their price target on shares of Chemed Corp. to $232.00 and gave the stock a “sector perform” rating in a report on Tuesday. Oppenheimer Holdings, Inc. increased their price target on shares of Chemed Corp. from $220.00 to $225.00 and gave the stock an “outperform” rating in a report on Friday, October 27th. Finally, Zacks Investment Research downgraded shares of Chemed Corp. from a “buy” rating to a “hold” rating in a report on Tuesday, September 26th. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company. Chemed Corp. currently has an average rating of “Hold” and an average price target of $224.33.
Large investors have recently made changes to their positions in the stock. Acrospire Investment Management LLC bought a new position in shares of Chemed Corp. during the 2nd quarter valued at approximately $120,000. Pacad Investment Ltd. grew its stake in shares of Chemed Corp. by 250.0% during the 2nd quarter. Pacad Investment Ltd. now owns 700 shares of the company’s stock valued at $143,000 after acquiring an additional 500 shares during the period. IFP Advisors Inc grew its stake in shares of Chemed Corp. by 1,504.5% during the 3rd quarter. IFP Advisors Inc now owns 706 shares of the company’s stock valued at $143,000 after acquiring an additional 662 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Chemed Corp. by 12.8% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 731 shares of the company’s stock valued at $150,000 after acquiring an additional 83 shares during the period. Finally, MCF Advisors LLC bought a new position in shares of Chemed Corp. during the 3rd quarter valued at approximately $152,000. Institutional investors own 97.24% of the company’s stock.
Chemed Corp. Company Profile
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with MarketBeat.com's FREE daily email newsletter.